Antibodies Archives

antibody drug conjugate adc small cancer treatment

News and Trends 12 Jul 2022

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […]

July 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 1 Jul 2022

License submitted to FDA for drug to help those with large B-cell lymphoma

A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company that says its core purpose is to improve the lives of people with cancer. Recently it announced its intent to submit the application for subcutaneous […]

July 1, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jun 2022

Watch: Antibody Analytics opens new health sciences center

A new facility dedicated to the advancement of medical research and drug development opened its doors recently in Motherwell, Scotland, as part of a major expansion. Antibody Analytics, one of Scotland’s authorities on immunology, officially cut the ribbon on its new health sciences research center. The unveiling of the new Antibody Analytics Discovery Centre, funded […]

June 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Jun 2022

Scancell to produce and clinically validate T cell redirecting bispecific antibodies

Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has announced it will develop its GlyMab antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. The UK company said this is a promising new therapeutic approach to treat cancer. TCB antibodies have dual-binding specificity, which […]

June 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 21 Jun 2022

Treatment for highly-sensitized kidney transplant patients approved and recommended

Treatment offered by Hansa Biopharma for the densensitization of highly sensitized adults prior to kidney transplants from deceased donors has been recommended by the UK’s National Institute for Health and Care Excellence (NICE). NICE considers Idefirix (imlifidase), made by Hansa, a Swedish company that specializes in enzyme technology for rare immunological conditions, to be a […]

June 21, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Jun 2022

ImCheck raises €96M in funding round

French biotech company ImCheck has announced funding of €96 million ($101.5 million) to investigate antibody drugs with the ability to activate the powerful immune cells called gamma delta T (gdT). The Marseille-based company hopes it will reach a wider range of cancer immunotherapy with the antibody drugs that include a lead candidate in the development […]

June 17, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Jun 2022

Spirea raises £2.4M to develop antibody drug conjugates in cancer

Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the funds to initiate its pipeline of ADCs in the treatment of solid tumors where they say there is a high unmet need. Targeted therapies, especially […]

June 16, 2022 - 3 minutesmins - By Liza Laws

argenx efgartigimod treatment autoimmune disease myasthenia gravis

News and Trends 21 Dec 2021

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues. Efgartigimod, to be marketed as Vyvgart, is an antibody fragment drug for use in adults with generalized myasthenia gravis. The FDA’s decision represents the first successful drug approval […]

December 21, 2021 - 4 minutesmins - By Anita Chakraverty

News and Trends 25 Nov 2021

Despite New Approvals, Covid-19 Treatments Lag Behind Vaccines

The EU recently added two drugs to its list of approved Covid-19 treatments. Yet with vaccines often in the spotlight, treatment options available to doctors remain few. Earlier this month, the European Commission gave its stamp of approval to two antibody treatments for Covid-19: regdanvimab from the South Korean firm Celltrion Healthcare, and a blend […]

November 25, 2021 - 6 minutesmins - By Victor Kotsev

News and Trends 30 Jun 2021

GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos

Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month, wondering if it overpaid for the Belgian company’s next-generation checkpoint inhibitor. GSK’s oncology deal with iTeos earlier this month centered on an antibody drug that blocks an immune checkpoint called TIGIT. The candidate is currently in phase I testing for […]

June 30, 2021 - 5 minutesmins - By Victor Kotsev

Best in Biotech 30 Jun 2021

Scotland’s Top 10 Biotech Companies to Watch Out For

Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial biotech. Let’s pick up the bagpipes as we tour the top 10 biotech companies in Scotland. Scotland is the UK’s second-most populous country, boasting picturesque scenery, a rich history, and a strong focus on sustainability. There is a diverse range […]

June 30, 2021 - 11 minutesmins - By Jonathan Smith

News and Trends 2 Apr 2020

Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment

The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease, also known as Covid-19. The therapeutic mRNA would be delivered directly into the lungs of symptomatic patients via nebulizers with nanoparticle aerosols. The mRNA could […]

April 2, 2020 - 3 minutesmins - By Anita Chakraverty

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us